Meeting
2024 ASCO Breakthrough
Cost-effectiveness of liquid biopsy for molecular profiling of newly diagnosed advanced non-squamous NSCLC in an Asian population.
Authors
Aaron C. Tan
Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
Aaron C. Tan , Sibo Liu , Nicholas Graves
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Thoracic Cancers,Breast Cancer,Gynecologic Cancer,Head and Neck Cancer,Hematologic Malignancies,Genetics/Genomics/Multiomics,Healthtech Innovations,Models of Care and Care Delivery,Viral-Mediated Malignancies,Other Malignancies or Topics
Sub Track
Diagnostics
Citation
J Clin Oncol 42, 2024 (suppl 23; abstr 178)
DOI
10.1200/JCO.2024.42.23_suppl.178
Abstract #
178
Poster Bd #
G8
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Cost analysis of targeted and immunotherapies in operable esophageal and non-small cell lung cancers.
First Author: Yahya Alwatari
Poster
2023 ASCO Quality Care Symposium
Comparative cost-effectiveness analysis of oral agents for advanced EGFR mutated and ALK-positive non-small cell lung cancer.
First Author: Dali Edwards
Poster
2021 ASCO Annual Meeting
Modeling the cost-effectiveness of adjuvant osimertinib in resected EGFR-mutant non-small cell lung cancer patients.
First Author: Christopher Lemmon
Poster
2016 ASCO Annual Meeting
Cost effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression.
First Author: Pedro Nazareth Aguiar